JP2016540773A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540773A5 JP2016540773A5 JP2016536710A JP2016536710A JP2016540773A5 JP 2016540773 A5 JP2016540773 A5 JP 2016540773A5 JP 2016536710 A JP2016536710 A JP 2016536710A JP 2016536710 A JP2016536710 A JP 2016536710A JP 2016540773 A5 JP2016540773 A5 JP 2016540773A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c1cc2nc(N)c(C(NN)=O)[n]2nc1* Chemical compound *c1cc2nc(N)c(C(NN)=O)[n]2nc1* 0.000 description 52
- NHRCDBNBRQOQCJ-UHFFFAOYSA-N CCOc(ccnc1)c1NC(c1c(cccc2)[n]2nc1N)=O Chemical compound CCOc(ccnc1)c1NC(c1c(cccc2)[n]2nc1N)=O NHRCDBNBRQOQCJ-UHFFFAOYSA-N 0.000 description 2
- DSEDUUFHHGXVHG-UHFFFAOYSA-N CN(CC1)CCC1Oc(ccnc1)c1NC(c1c(N)nc2[n]1nc(C(F)(F)F)cc2)=O Chemical compound CN(CC1)CCC1Oc(ccnc1)c1NC(c1c(N)nc2[n]1nc(C(F)(F)F)cc2)=O DSEDUUFHHGXVHG-UHFFFAOYSA-N 0.000 description 2
- MIMBKZPNNFLXDB-UHFFFAOYSA-N CN(CC1)CCC1Oc(ccnc1)c1NC(c1c(N)nc2[n]1nccc2)=O Chemical compound CN(CC1)CCC1Oc(ccnc1)c1NC(c1c(N)nc2[n]1nccc2)=O MIMBKZPNNFLXDB-UHFFFAOYSA-N 0.000 description 2
- SGFTYMGAFPRPNP-UHFFFAOYSA-N CN(CC1)CCN1C(C(CC1)CCN1c(c(F)cnc1)c1NC(c1c(cccc2)[n]2nc1N)=O)=O Chemical compound CN(CC1)CCN1C(C(CC1)CCN1c(c(F)cnc1)c1NC(c1c(cccc2)[n]2nc1N)=O)=O SGFTYMGAFPRPNP-UHFFFAOYSA-N 0.000 description 2
- VOTOWVOBHDEJEB-UHFFFAOYSA-N Nc1n[n](cccc2)c2c1C(Nc(cncc1)c1N1CCCCC1)=O Chemical compound Nc1n[n](cccc2)c2c1C(Nc(cncc1)c1N1CCCCC1)=O VOTOWVOBHDEJEB-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2013/073482 WO2015084384A1 (en) | 2013-12-06 | 2013-12-06 | Compounds useful as inhibitors of atr kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016540773A JP2016540773A (ja) | 2016-12-28 |
| JP2016540773A5 true JP2016540773A5 (enExample) | 2017-02-09 |
Family
ID=49877037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536710A Pending JP2016540773A (ja) | 2013-12-06 | 2013-12-06 | Ａｔｒキナーゼの阻害剤として有用な化合物 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3077393A1 (enExample) |
| JP (1) | JP2016540773A (enExample) |
| WO (1) | WO2015084384A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| EP3355926B1 (en) | 2015-09-30 | 2025-12-24 | Vertex Pharmaceuticals Inc. | Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| BR112021004935A2 (pt) | 2018-09-26 | 2021-06-01 | Merck Patent Gmbh | combinação de antagonista de pd-1, inibidor de atr e agente de platinação para tratamento de câncer |
| EP3866785A1 (en) | 2018-10-15 | 2021-08-25 | Merck Patent GmbH | Combination therapy utilizing dna alkylating agents and atr inhibitors |
| KR20230088709A (ko) | 2020-10-16 | 2023-06-20 | 상하이 드 노보 파마테크 컴퍼니 리미티드 | 트리헤테로사이클릭 유도체, 이의 약학적 조성물 및 용도 |
| CN115466258A (zh) * | 2021-06-11 | 2022-12-13 | 成都苑东生物制药股份有限公司 | Atr抑制剂及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5238697B2 (ja) * | 2006-08-04 | 2013-07-17 | 武田薬品工業株式会社 | 縮合複素環誘導体およびその用途 |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| CA2825098C (en) * | 2011-01-27 | 2020-03-10 | Universite De Montreal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
-
2013
- 2013-12-06 JP JP2016536710A patent/JP2016540773A/ja active Pending
- 2013-12-06 WO PCT/US2013/073482 patent/WO2015084384A1/en not_active Ceased
- 2013-12-06 EP EP13811718.9A patent/EP3077393A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015515478A5 (enExample) | ||
| JP2016512816A5 (enExample) | ||
| HRP20211034T1 (hr) | 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze | |
| JP2016512239A5 (enExample) | ||
| JP2014510151A5 (enExample) | ||
| JP2016512815A5 (enExample) | ||
| RU2017101189A (ru) | Способ лечения рака с использованием комбинации ингибиторов снк1 и atr | |
| JP2016540773A5 (enExample) | ||
| JP2016501244A5 (enExample) | ||
| JP2017186385A5 (enExample) | ||
| JP2013529643A5 (enExample) | ||
| CN108771681B (zh) | 作为dna-pk抑制剂的化合物及其氘化衍生物的共晶 | |
| ES2663222T3 (es) | Derivados de pirazina útiles como inhibidores de la quinasa ATR | |
| SI2833973T1 (en) | Compounds useful as inhibitors of ATR kinase and their combination therapy | |
| JP2013529199A5 (enExample) | ||
| CN105899493B (zh) | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 | |
| JP2013526540A5 (enExample) | ||
| RU2605335C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2013526539A5 (enExample) | ||
| CN114174292A (zh) | 作为atr激酶抑制剂的取代的2-吗啉代吡啶衍生物 | |
| JP2013526541A5 (enExample) | ||
| JP2012508260A5 (enExample) | ||
| Fathi Karkan et al. | Cisplatin-loaded superparamagnetic nanoparticles modified with PCL-PEG copolymers as a treatment of A549 lung cancer cells | |
| Ning et al. | Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy | |
| Kolarović | Application of a widely-used tropical anti-worm agent, mebendazole, in modern oncology |